ARCT Arcturus Therapeutics Holdings Inc
Company Analysis
Latest News
π΄ Arcturus Therapeutics is trading 5% down today amid broader risk-off sentiment
Arcturus Therapeutics is trading at $10.48, down 5.33%, amid broader risk-off sentiment; no clear company-specific catalyst was identified for the October 22...
π΄ Arcturus Therapeutics is trading 6.5% down in pre-market with no company-specific cause identified
Arcturus Therapeutics is trading 6.5% lower at $10.35 in pre-market, as weaker risk sentiment and geopolitical tensions may be contributing; no...
π’ Arcturus Therapeutics is trading 10.2% up today amid broader biotech rally
Arcturus Therapeutics is trading at $11.48, up 10.22%, with the move appearing to track a broader biotech rally. - No clear Arcturus-specific announcement was...
π’ Arcturus Therapeutics rises 5.1% β Biotech Sector Surges on M&A Activity and Positive Clinical Trial Data
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
π΄ Arcturus Therapeutics is trading 7.8% down today amid biotech-sector weakness
Arcturus Therapeutics is trading at $10.39, with a -7.81% change amid biotech-sector weakness; available evidence does not establish a direct cause for the...
π’ Arcturus Therapeutics is trading 7.73% up in pre-market β no clear catalyst identified
Arcturus Therapeutics is trading at $11.98, up 7.73%, with no clear catalyst identified for the October 15 pre-market gain. - No new company-specific...
π΄ Arcturus Therapeutics is trading 5.2% down today as hotter-than-expected CPI puts pressure on stocks
Arcturus Therapeutics is trading at $11.40, down 5.2%, amid broader market pressure following hotter-than-expected September inflation data. - September...
π΄ Arcturus Therapeutics is trading 5.8% down today alongside a 2.01% drop in biotech ETF XBI
Arcturus Therapeutics is trading at $11.88, down 5.83%, with biotech-sector weakness the clearest available context. - Biotech ETF XBI is down 2.01%, but this...
π΄ Arcturus Therapeutics is trading 5% down with no clear company-specific catalyst
Arcturus Therapeutics is trading at $13.05, down 5.01%, with no clear company-specific announcement or catalyst identified for the October 12 decline. -...
Arcturus Jumps 10% on Leerink Upgrade β But Can an mRNA Biotech Burning $60 Million a Year Justify the Optimism?
Shares of Arcturus Therapeutics surged 10.4% to $14.21 Friday after Leerink Partners analyst Lili Nsongo hiked the firm's price target from $13 to $19 while...
π’ Arcturus Therapeutics is trading 10% up today with Leerink's $19 target potentially supporting gains
Arcturus Therapeutics is trading at $14.21, up 10.41%, with Leerink Partnersβ price-target increase potentially supporting the gain. - On October 9, Leerink...
π’ Arcturus Therapeutics is trading 5.4% up today after Leerink raised its target to $19
Arcturus Therapeutics is trading at $13.57, up 5.44%, with Leerink Partnersβ analyst update potentially supporting the move. - On October 9, 2026, Leerink...
Leerink Partners Raises Price Target for Arcturus Therapeutics
Leerink Partners maintained its "Outperform" rating for Arcturus Therapeutics (ARCT). The firm increased its price target from $13.00 to $19.00. This marks a...
π΄ Arcturus Therapeutics is trading 10% down amid biotech-sector weakness
Arcturus Therapeutics is trading 10.03% down at $13.19, with no clear company-specific announcement or event explaining the October 6 decline; broader biotech...
π΄ Arcturus Therapeutics is trading 5.5% down today
Arcturus Therapeutics is trading at $13.86, down -5.46%, with no confirmed company-specific announcement or event surfaced in the search to explain the October...
π’ Arcturus Therapeutics is trading 10.28% up amid broader market gains
Arcturus Therapeutics is trading 10.28% higher at $14.37, with the gain appearing consistent with broader risk-on sentiment. - The S&P 500 is up 0.70% and the...
π’ Arcturus Therapeutics is trading 5.7% up today amid a positive broader-market backdrop
Arcturus Therapeutics is trading 5.7% higher at $13.78, with no fresh company-specific catalyst evident. - The investor-relations page shows no October 5...
π΄ Arcturus Therapeutics is trading 5% down with no clear catalyst identified
Arcturus Therapeutics is trading at $13.73, down 5.05%, with no clear company-specific catalyst identified for the September 29 decline. - The latest major...
π’ Arcturus Therapeutics is trading 5% up
Arcturus Therapeutics is trading 5.08% higher at $14.55, with no specific catalyst identified for the move. - No company-specific announcement on September...
π΄ Arcturus Therapeutics is trading 5% down in pre-market alongside S&P 500 and Nasdaq declines
Arcturus Therapeutics is trading 5.27% lower at $13.12 in pre-market; no company-specific announcement explaining the September 28 move was identified. - This...